Amwell (AMWL) Q1 2023: Converge Drives 29% of Visits, Accelerating Hybrid Care Adoption
Amwell’s Converge platform is now powering over a third of all visits, reflecting rapid migration and client validation. Strategic wins and expanding automated care programs are shifting the business toward high-value, integrated digital health services. Management reiterates full-year guidance, signaling confidence in execution despite macro caution and a major non-cash impairment.
Summary
- Hybrid Platform Penetration: Converge now underpins a growing share of visits, anchoring Amwell’s competitive edge in digital-first care.
- Strategic Client Expansion: High-profile wins and deeper payer/provider integrations reinforce the platform’s stickiness and value proposition.
- Profitability Levers in Focus: Declining R&D and migration costs set up margin recovery as legacy transitions wind down.
Business Overview
Amwell is a digital health infrastructure company that enables hybrid care delivery for payers and providers. The company generates revenue through software subscriptions, visit-based fees via its Amwell Medical Group (AMG), and professional services supporting platform deployments and customizations. Its core segments include Converge, a unified hybrid care platform, AMG clinical services, and a portfolio of automated and asynchronous care programs. Amwell’s client base spans health systems, payers, and innovators, with a focus on digital-first healthcare transformation.
Performance Analysis
Amwell reported flat total revenue year-over-year, as professional services and subscription lines absorbed the impact of prior period churn and a shift in implementation activity. The migration to Converge was a central operational theme, with 36% of all visits now occurring on the new platform, up from 28% at year-end. While total visits dipped 4% from last year’s COVID-driven peak, scheduled visits rose sequentially and now account for 68% of all visits—evidence of the platform’s deeper integration into routine care delivery.
Active provider count grew 8%, driven by client-employed clinicians, while AMG visit revenue climbed 6% year-over-year, reflecting both volume and mix dynamics. Gross margin compressed to 39.5% due to higher clinician onboarding and migration-related professional services, but management expects margin improvement as subscription revenue and services normalize post-transition. R&D and G&A costs declined sequentially, supporting the company’s plan to exit the year with a meaningfully lower cost base. A $330 million non-cash goodwill impairment, tied to share price declines, dominated GAAP results but did not affect liquidity, with $507 million in cash and marketable securities on hand.
- Converge Migration Momentum: Over a third of all visits now flow through Converge, supporting scale and client stickiness.
- Visit Mix Normalizes: Scheduled care remains elevated, while urgent care volumes reflected seasonal flu dynamics.
- Cost Structure Reset: R&D and G&A expense reductions set up EBITDA leverage as transition costs abate.
Management’s reiteration of full-year revenue and EBITDA guidance signals confidence in the underlying demand and execution cadence, even as macro caution persists among clients.
Executive Commentary
"We made great progress with health system migrations and payer deployments are underway. Strategic clients went live this quarter, providing valuable in-market validation of the power and scale of Converge, our unique whole-person, one-stop-shop platform that supports the delivery of hybrid healthcare."
Dr. Ido Schoenberg, Chairman & CEO
"Active providers continues to be an important indicator of the sustained value our clients see in our platform. We ended the first quarter with 108,000 active providers representing growth of 8% compared to a year ago. We anticipate that our number of active providers will continue to increase as we migrate existing and implement new clients onto our Converge platform."
Bob Shepardson, CFO
Strategic Positioning
1. Platform Consolidation and Client Migration
Converge is now the central pillar of Amwell’s go-to-market, with migrations accelerating across both health systems and payers. The platform’s ability to integrate with major EHRs (electronic health records) and support hybrid care models is driving adoption and reference wins, such as the enterprise-wide go-live at Health Partners and a large Blue Cross Blue Shield expansion.
2. Automated and Asynchronous Care Expansion
Amwell is packaging automated care programs targeting high-cost, high-need areas, including maternity, ED discharge, and chronic disease management. These programs are validated by client outcomes, such as a 57% reduction in nurse calls and $4 million in annualized ED savings at Prisma Health, demonstrating the ROI imperative for health systems under budget strain.
3. Evidence-Driven Sales and Modular Solutioning
The company has shifted to a consultative, solutions-oriented sales approach, leveraging modularity and best practice references to tailor deployments. This model increases stickiness and wallet share, as clients increasingly seek to consolidate vendors and deploy digital-first infrastructure rather than point telehealth solutions.
4. Ecosystem Partnerships and Third-Party Integration
Converge’s architecture supports rapid integration of third-party solutions, exemplified by the partnership with Dario Health for cardiometabolic care. This “app store” model enables Amwell to expand its offering without costly M&A, tapping into its 2,000-hospital and 90-million-lives install base to drive adoption and utilization of new programs.
5. Cost Discipline and Margin Recovery
Management is executing on a cost reset, with R&D and G&A trending down as Converge development peaks and migration work winds down. EBITDA leverage is expected as subscription and services revenue mix recovers, and as onboarding and custom implementation costs normalize post-transition.
Key Considerations
Amwell’s Q1 marks a pivotal phase as the company transitions from legacy telehealth to a unified hybrid care platform, with operational and financial implications that will shape its trajectory over the next several quarters.
Key Considerations:
- Client Win Quality: Recent strategic wins highlight Amwell’s ability to expand existing relationships and displace legacy vendors, supporting its move upmarket.
- Migration Execution Risk: The pace and complexity of Converge migrations remain a critical watchpoint, especially as payer deployments ramp in the coming quarters.
- Automated Program Validation: Demonstrated ROI from automated care programs is resonating with clients under cost pressure, but scaling these wins will be key.
- Revenue Mix Evolution: As professional services and subscription revenue normalize post-transition, margin and cash flow improvement will depend on sustained client adoption and upsell activity.
Risks
Amwell faces ongoing macro uncertainty, with hospital and health plan budgets under pressure and cautious spending patterns persisting. While strategic client retention has been strong, churn among smaller clients during the re-platforming phase underscores continued competitive risk at the lower end of the market. The company’s reliance on successful, timely migrations and client go-lives for revenue recognition introduces operational risk, and the transition to a solutions-based sales model will require continued execution discipline. A large non-cash goodwill impairment also signals market skepticism around future growth and profitability.
Forward Outlook
For Q2 2023, Amwell guided to:
- Substantial increase in services and care points revenue as strategic client implementations ramp.
- Flat to modestly higher subscription revenue as new migrations offset prior churn.
For full-year 2023, management reiterated guidance:
- $275 to $285 million in total revenue
- Adjusted EBITDA of negative $150 to negative $160 million
Management emphasized execution on client migrations, expanding automated program adoption, and cost discipline as the key drivers supporting guidance. The outlook assumes continued macro caution but no material deterioration or improvement in client spending.
- Majority of health system migrations to be completed in 2023
- Payer migrations to drive incremental volume into early 2024
Takeaways
Amwell’s Q1 confirms the company’s transition from a legacy telehealth vendor to a hybrid care platform leader is well underway, with operational momentum and strategic client wins supporting the long-term thesis.
- Platform Maturity: Converge’s growing share of visits and client migrations are building a defensible moat and driving higher-value, integrated care delivery.
- Cost and Margin Inflection: Expense discipline and post-migration normalization set up EBITDA leverage, with execution on bookings and implementations the key swing factor.
- Next Phase Watchpoint: Investors should monitor the pace of payer migrations, automated program scaling, and the durability of new client wins as the company exits its transition year.
Conclusion
Amwell’s Q1 showcased tangible progress in platform migration, strategic client expansion, and cost discipline, even as macro caution and a major impairment weigh on sentiment. The company’s execution on Converge adoption and automated care scaling will determine its ability to translate operational wins into sustained financial improvement and market leadership.
Industry Read-Through
Amwell’s results highlight a decisive industry shift toward unified, digital-first hybrid care infrastructure, with health systems and payers increasingly seeking vendor consolidation, rapid ROI, and modular solutioning. The company’s success in integrating automated programs and third-party partnerships signals that platform extensibility and evidence-based outcomes are becoming table stakes in digital health. For peers and emerging competitors, the bar is rising for interoperability, referenceable outcomes, and consultative sales models. The normalization of scheduled virtual care and the growing importance of asynchronous automation point to a future where hybrid care is not just a pandemic response, but a structural evolution in healthcare delivery. Platform players able to aggregate, integrate, and demonstrate ROI will be best positioned as health systems and payers rationalize their digital investments.